SI
Sofinnova Investments Portfolio holdings
AUM
$1.47B
This Quarter Return
+3.25%
1 Year Return
+17.43%
3 Year Return
+337.79%
5 Year Return
+424.38%
10 Year Return
–
AUM
$1.56B
AUM Growth
+$1.56B
(-5.2%)
Cap. Flow
-$70.3M
Cap. Flow
% of AUM
-4.51%
Top 10 Holdings %
Top 10 Hldgs %
66.12%
Holding
83
New
13
Increased
14
Reduced
20
Closed
13
Top Buys
| 1 |
AbbVie
ABBV
|
$29.4M |
| 2 |
BPMC
Blueprint Medicines
BPMC
|
$18.7M |
| 3 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
$17.3M |
| 4 |
Zoetis
ZTS
|
$14.8M |
| 5 |
Zymeworks
ZYME
|
$11.9M |
Top Sells
| 1 |
XLRN
Acceleron Pharma Inc.
XLRN
|
$33.4M |
| 2 |
Biogen
BIIB
|
$21.9M |
| 3 |
Neurocrine Biosciences
NBIX
|
$19.8M |
| 4 |
Insulet
PODD
|
$19.2M |
| 5 |
Vertex Pharmaceuticals
VRTX
|
$17.8M |
Sector Composition
| 1 | Healthcare | 98.91% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
NCNA
26
NuCana
NCNA
$5.8M
| $14.4M | 0.86% |
5,599,999
| – | – |
|
|
CMPI
27
DELISTED
Checkmate Pharmaceuticals, Inc. Common Stock
CMPI
| $14.3M | 0.85% |
3,606,707
| – | – |
|
28
Kura Oncology
KURA
$732M
| $14.1M | 0.84% |
755,121
+310,749
| +70% | +$5.82M |
|
|
AGEN
29
Agenus
AGEN
$136M
| $12.3M | 0.73% |
2,344,410
-425,490
| -15% | -$2.23M |
|
|
30
Zymeworks
ZYME
$1.07B
| $11.9M | 0.71% |
+410,619
| New | +$11.9M |
|
31
Travere Therapeutics
TVTX
$1.75B
| $10.6M | 0.63% |
+437,280
| New | +$10.6M |
|
32
Exelixis
EXEL
$9.95B
| $10.3M | 0.61% |
488,414
-591,267
| -55% | -$12.5M |
|
|
MRTX
33
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $10.1M | 0.6% |
56,900
-21,638
| -28% | -$3.83M |
|
|
34
Biogen
BIIB
$20.8B
| $9.4M | 0.56% |
33,220
-77,380
| -70% | -$21.9M |
|
|
KDMN
35
DELISTED
Kadmon Holdings, Inc.
KDMN
| $9.11M | 0.54% |
+1,046,312
| New | +$9.11M |
|
|
CCXI
36
DELISTED
ChemoCentryx, Inc.
CCXI
| $8.85M | 0.52% |
517,708
+52,071
| +11% | +$890K |
|
37
PTC Therapeutics
PTCT
$4.41B
| $8.56M | 0.51% |
230,019
-351,921
| -60% | -$13.1M |
|
|
ITCI
38
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $8.48M | 0.5% |
227,419
-85,740
| -27% | -$3.2M |
|
39
ALX Oncology
ALXO
$54.6M
| $7.92M | 0.47% |
+107,220
| New | +$7.92M |
|
40
Syndax Pharmaceuticals
SNDX
$1.39B
| $7.91M | 0.47% |
+413,841
| New | +$7.91M |
|
41
Celldex Therapeutics
CLDX
$1.57B
| $7.4M | 0.44% |
137,032
+2,308
| +2% | +$125K |
|
|
XLRN
42
DELISTED
Acceleron Pharma Inc.
XLRN
| $6.81M | 0.4% |
39,589
-194,049
| -83% | -$33.4M |
|
43
Immatics
IMTX
$662M
| $6.22M | 0.37% |
478,216
+34,846
| +8% | +$453K |
|
|
CTIC
44
DELISTED
CTI BioPharma Corp. (DE) Common Stock
CTIC
| $6.12M | 0.36% |
2,074,714
+1,903,095
| +1,109% | +$5.61M |
|
|
ISEE
45
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| $5.8M | 0.34% |
+357,400
| New | +$5.8M |
|
|
AMRN
46
Amarin Corp
AMRN
$311M
| $5.46M | 0.32% |
1,069,968
-100,616
| -9% | -$513K |
|
47
Regenxbio
RGNX
$498M
| $5.35M | 0.32% |
127,593
-300,147
| -70% | -$12.6M |
|
48
Protagonist Therapeutics
PTGX
$3.62B
| $5.28M | 0.31% |
297,709
-151,373
| -34% | -$2.68M |
|
49
Guardant Health
GH
$8.11B
| $5M | 0.3% |
+40,000
| New | +$5M |
|
|
JNCE
50
DELISTED
Jounce Therapeutics, Inc. Common Stock
JNCE
| $4.74M | 0.28% |
637,347
+12,591
| +2% | +$93.5K |
|